Blocking VEGFR2 signaling by anti‐VEGF‐A or VEGFR‐2 antibodies or VEGFR small‐molecule tyrosine kinase inhibitors showed confirmed anti‐tumor activity in both preclinical and clinical practice.1, 2, 3. Here, KDR is linked to neoplasm.